Computational Characterization of Antibody–Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach

SILCS-Biologics combines the accuracy of the SILCS ligand docking and protein-protein interaction technologies to allow for comprehensive mapping of the binding locations and affinities of excipients on the entire surface of protein therapeutics including monoclonal antibodies (mAb).  Application of the SILCS-Biologics approach to the NIST mAb identified calculated SILCS metrics for a collection of eight […]

Continue Reading

SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service Suite

SilcsBio and Dalriada to tap areas of expertise in drug design and development to accelerate clients’ programs in development of therapeutic treatments against diseases with unmet needs, initiated with COVID-19 FOR IMMEDIATE RELEASE: June 11, 2020, Baltimore, MD and Toronto, ON – SilcsBio, a technology company that develops innovative software and provides services for structure-based […]

Continue Reading